Literature DB >> 17627552

Non-alcoholic fatty liver disease in the metabolic syndrome.

Giuseppe Palasciano1, Antonio Moschetta, Vincenzo O Palmieri, Ignazio Grattagliano, Gianluca Iacobellis, Piero Portincasa.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17627552     DOI: 10.2174/138161207781039652

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

Review 1.  Cholecystectomy and risk of metabolic syndrome.

Authors:  Agostino Di Ciaula; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Eur J Intern Med       Date:  2018-04-26       Impact factor: 4.487

2.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

3.  Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.

Authors:  Wenqian Fang; Zhiyong Deng; Feriel Benadjaoud; Chongzhe Yang; Guo-Ping Shi
Journal:  Transl Res       Date:  2020-05-11       Impact factor: 7.012

4.  Roles of alcohol drinking pattern in fatty liver in Japanese women.

Authors:  Akio Moriya; Yoshiaki Iwasaki; Souhei Ohguchi; Eizo Kayashima; Tadahiko Mitsumune; Fusao Ikeda; Masaharu Ando; Kazuhide Yamamoto
Journal:  Hepatol Int       Date:  2013-07-17       Impact factor: 6.047

5.  A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.

Authors:  Ignazio Grattagliano; Catia V Diogo; Maria Mastrodonato; Ornella de Bari; Michele Persichella; David Q H Wang; Adriana Liquori; Domenico Ferri; Maria Rosaria Carratù; Paulo J Oliveira; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

6.  Alternative Mechanism for White Adipose Tissue Lipolysis after Thermal Injury.

Authors:  Li Diao; David Patsouris; Ali-Reza Sadri; Xiaojing Dai; Saeid Amini-Nik; Marc G Jeschke
Journal:  Mol Med       Date:  2015-12-29       Impact factor: 6.354

7.  Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome.

Authors:  Guang Yang; Leylla Badeanlou; Jacek Bielawski; Amanda J Roberts; Yusuf A Hannun; Fahumiya Samad
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-12       Impact factor: 4.310

8.  Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Authors:  Feng-Shang Zhu; Su Liu; Xi-Mei Chen; Zhi-Gang Huang; Dong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

9.  Renal protective effects of Porphyra dentate aqueous extract in diabetic mice.

Authors:  Pei-Chun Chao; Cheng-Chin Hsu; Wen-Hu Liu
Journal:  Biomedicine (Taipei)       Date:  2014-08-13

10.  Hepatoprotective Effects of Insect Extracts in an Animal Model of Nonalcoholic Fatty Liver Disease.

Authors:  A-Rang Im; Won-Kyung Yang; Yang-Chun Park; Seung Hyung Kim; Sungwook Chae
Journal:  Nutrients       Date:  2018-06-07       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.